GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Cash-to-Debt

ClearPoint Neuro (ClearPoint Neuro) Cash-to-Debt : 1.66 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ClearPoint Neuro's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.66.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ClearPoint Neuro could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for ClearPoint Neuro's Cash-to-Debt or its related term are showing as below:

CLPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68   Med: 1.43   Max: 4.41
Current: 1.66

During the past 13 years, ClearPoint Neuro's highest Cash to Debt Ratio was 4.41. The lowest was 0.68. And the median was 1.43.

CLPT's Cash-to-Debt is ranked worse than
52.56% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs CLPT: 1.66

ClearPoint Neuro Cash-to-Debt Historical Data

The historical data trend for ClearPoint Neuro's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ClearPoint Neuro Cash-to-Debt Chart

ClearPoint Neuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.31 0.83 4.41 3.13 1.66

ClearPoint Neuro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 2.68 1.86 1.74 1.66

Competitive Comparison of ClearPoint Neuro's Cash-to-Debt

For the Medical Devices subindustry, ClearPoint Neuro's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's Cash-to-Debt falls into.



ClearPoint Neuro Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ClearPoint Neuro's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

ClearPoint Neuro's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ClearPoint Neuro  (NAS:CLPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


ClearPoint Neuro Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro (ClearPoint Neuro) Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103